Litigation Details for Alkermes Pharma Ireland Limited v. Mylan Pharmaceuticals Inc. (D. Del. 2012)

« Back to Dashboard

Alkermes Pharma Ireland Limited v. Mylan Pharmaceuticals Inc. (D. Del. 2012)

Docket		Date Filed	2012-12-07
Court	District Court, D. Delaware	Date Terminated	2014-05-19
Cause	35:271 Patent Infringement	Assigned To	Sue Lewis Robinson
Jury Demand	None	Referred To
Patents	6,228,398
Link to Docket	External link to docket

Details for Alkermes Pharma Ireland Limited v. Mylan Pharmaceuticals Inc. (D. Del. 2012)

Date Filed	Document No.	Description	Snippet	Link To Document
2012-12-07				External link to document

Alkermes Pharma Ireland v. Mylan Pharmaceuticals, 1:12-cv-01673: Litigation Summary and Patent Analysis

Last updated: October 4, 2026

Alkermes Pharma Ireland Limited sued Mylan Pharmaceuticals Inc. in the U.S. District Court for the District of Delaware after Mylan filed an abbreviated new drug application seeking approval for a generic version of Vivitrol, Alkermes’ extended-release injectable naltrexone product. The case was an ANDA patent dispute focused on Alkermes’ long-acting microsphere drug-delivery technology.

The litigation did not produce a reported merits opinion establishing that Mylan’s proposed product infringed a valid, enforceable patent. The case was later terminated, consistent with resolution by settlement or another non-trial disposition reflected in the docket rather than a public final judgment after trial.[1]

What drug and technology were at issue in Alkermes v. Mylan?

The dispute concerned Vivitrol, an extended-release injectable suspension containing naltrexone. FDA approved Vivitrol for alcohol dependence and later for prevention of relapse to opioid dependence following opioid detoxification.[2]

Vivitrol uses polymeric microspheres to release naltrexone over an extended period after intramuscular administration. The formulation is materially different from an immediate-release oral naltrexone tablet because it combines:

• A depot injectable dosage form
• Biodegradable polymer microspheres
• Controlled release over approximately one month
• A reconstitution and administration process before injection

The complex formulation increased the potential relevance of formulation, manufacturing, and drug-delivery patents beyond the active ingredient itself.

When was the Alkermes v. Mylan case filed?

Alkermes filed the case in 2012 in the District of Delaware under case number 1:12-cv-01673. The action followed Mylan’s ANDA filing and Paragraph IV certification concerning patents listed for Vivitrol in the FDA’s Orange Book.[1]

Under the Hatch-Waxman framework, Alkermes’ filing triggered the statutory 30-month stay of FDA approval, subject to statutory exceptions. The litigation therefore had direct commercial significance because Mylan could not receive final approval during the stay unless the court resolved the dispute earlier or the stay was otherwise terminated.[3]

Item	Information
Plaintiff	Alkermes Pharma Ireland Limited
Defendant	Mylan Pharmaceuticals Inc.
Court	U.S. District Court for the District of Delaware
Case number	1:12-cv-01673
Product	Vivitrol
Active ingredient	Naltrexone
Dosage form	Extended-release injectable microsphere suspension
Litigation type	ANDA patent infringement action
Filing period	2012
Public merits trial outcome	No reported final merits judgment establishing infringement and validity
Disposition	Terminated after the parties’ litigation activity, without a reported public trial verdict

What patents protected Vivitrol?

The core patent estate associated with Vivitrol included patents directed to extended-release microsphere compositions, injectable depot formulations, and related drug-delivery technology. The most historically significant Alkermes patent family included U.S. Patent No. 6,228,398, which covered extended-release microsphere compositions and related controlled-release applications.[4]

The litigation record and Orange Book framework should be distinguished:

1. A patent may cover the drug product or its formulation.
2. A patent may cover a method of treatment.
3. A patent may be listed in the Orange Book only if it meets FDA listing requirements.
4. A patent’s listing does not establish validity or infringement.

The Vivitrol estate was commercially important because formulation protection can delay generic competition even after basic active-ingredient protection has expired. Naltrexone itself is an old active ingredient. The competitive barrier depended on the injectable depot formulation, release profile, manufacturing process, and regulatory equivalence requirements.

What formulation patents were relevant?

The relevant protection centered on controlled-release microspheres rather than naltrexone’s chemical composition. The key technical issues in a Vivitrol-type product include:

• Polymer selection and composition
• Particle-size distribution
• Drug loading
• Release kinetics
• Residual solvent levels
• Syringeability and reconstitution
• Physical stability
• Manufacturing reproducibility
• Bioequivalence or equivalent therapeutic performance

A generic applicant could avoid literal infringement by changing formulation parameters, but those changes could create FDA development risk. A formulation that differed from Vivitrol’s release profile might require additional clinical or pharmacokinetic support and could fail to qualify for the intended ANDA pathway.

What was Mylan’s Paragraph IV challenge?

Mylan’s ANDA challenge placed the patent dispute within the Hatch-Waxman litigation process. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or would not be infringed by the proposed generic product.[3]

The central legal questions were therefore likely to include:

• Whether Mylan’s proposed microsphere formulation fell within the asserted claims
• Whether the asserted claims were anticipated or obvious
• Whether the claims were enabled and adequately described
• Whether the patent owner could prove infringement based on the ANDA and proposed product
• Whether any patent-related defenses affected enforceability

In an ANDA case, infringement analysis generally focuses on the product described in the ANDA, not on a later commercial product that may differ from the filing. The ANDA documents, formulation specifications, manufacturing steps, and proposed labeling can become central evidence.

What was the litigation status and outcome?

The publicly available docket does not show a reported trial verdict or a published decision finally resolving the principal validity and infringement issues between Alkermes and Mylan.[1]

That distinction matters. Termination of an ANDA case does not mean that the asserted patents were upheld. It also does not mean that Mylan’s product was found non-infringing. A terminated case may reflect:

• A confidential settlement
• Withdrawal or amendment of an ANDA
• A change in the proposed product
• A licensing arrangement
• Commercial resolution after regulatory or business changes
• Dismissal following expiration or narrowing of the relevant patent claims

The absence of a public merits decision limits the precedential value of the case. It does not eliminate its commercial value as a signal of Alkermes’ willingness to enforce formulation patents against generic injectable-drug developers.

Did the case involve a patent settlement?

The public docket does not provide a reported, detailed settlement agreement establishing the parties’ precise entry terms. Any settlement date, authorized generic provision, royalty terms, or launch date should not be inferred from the case number alone.

For pharmaceutical settlements, the commercially material provisions typically include:

• Generic launch date
• Whether launch is contingent on FDA approval
• Authorized generic rights
• Royalty payments
• Restrictions on manufacturing or supply
• Resolution of later-issued patents
• Covenants not to sue
• Scope of releases
• Treatment of future ANDA supplements

Where the agreement is confidential, the absence of public terms prevents a reliable calculation of the settlement’s effect on Vivitrol’s exclusivity period.

What was the FDA and Orange Book significance?

Vivitrol’s regulatory protection was based on several overlapping mechanisms:

Protection	Relevance to Vivitrol
New drug approval	Established FDA approval for long-acting injectable naltrexone
Orange Book patents	Created the basis for Paragraph IV litigation
Regulatory exclusivity	Depended on the approval date and statutory category
Formulation patents	Protected the microsphere depot product
Method-of-use patents	Could restrict labeled use, subject to skinny-label issues
Manufacturing know-how	Could create practical barriers not fully reflected in the Orange Book

The Orange Book does not capture every commercial barrier. Manufacturing know-how, specialized equipment, scale-up experience, and control of critical formulation parameters can delay generic entry even after patent barriers weaken.

For a generic injectable microsphere product, FDA approval may require substantial product-development work. An ANDA applicant must demonstrate pharmaceutical equivalence and bioequivalence or otherwise satisfy FDA’s product-specific requirements. The regulatory burden can be higher where the reference product has a complex formulation and no straightforward analytical surrogate for clinical performance.[5]

How strong was the Alkermes patent estate?

The estate had meaningful technical strength because it focused on a difficult-to-reproduce delivery system rather than an easily substitutable small-molecule tablet. Its commercial strength depended on four factors.

Technical scope

Microsphere patents can cover formulation composition, particle characteristics, release performance, and manufacturing conditions. Broad claims create stronger exclusionary potential, but they also face greater exposure to written-description, enablement, anticipation, and obviousness challenges.

Remaining patent term

The practical value of any asserted patent depended on its expiration date, patent-term adjustment, patent-term extension, and the time required for FDA approval. A patent with only a short remaining term may still support settlement leverage if the ANDA applicant faces a 30-month stay and significant development costs.

Claim construction risk

Terms describing release rates, polymer ratios, particle sizes, and formulation properties can materially affect infringement. Narrow construction can permit design-around strategies. Broad construction can increase invalidity risk.

Manufacturing dependence

Even if a generic applicant avoided literal infringement, it still needed to manufacture a product with comparable release and performance characteristics. That created a separate operational barrier for Mylan and other potential entrants.

What generic entry risks existed?

The principal generic-entry scenarios were:

Scenario	Effect on Alkermes
Patent settlement with delayed entry	Preserved revenue through the agreed launch date
Mylan withdrawal or delay	Extended practical exclusivity without a court victory
Non-infringement or invalidity ruling	Accelerated competitive entry
Product redesign	Reduced litigation exposure but increased FDA and manufacturing risk
Launch at risk	Exposed Mylan to damages and injunction risk
Delayed FDA approval	Reduced immediate threat even if patents were overcome

For Vivitrol, generic entry would likely have affected pricing, payer contracting, addiction-treatment procurement, and institutional purchasing. Injectable products can experience slower substitution than oral generics because providers must evaluate administration logistics, supply reliability, training, reimbursement, and product handling.

How does Vivitrol compare with conventional oral naltrexone?

Vivitrol’s patent and commercial position differed from oral naltrexone.

Issue	Vivitrol	Oral naltrexone
Dosage form	Monthly intramuscular injection	Daily oral tablet
Primary barrier	Complex formulation and delivery technology	Limited product differentiation
Adherence profile	Reduces daily dosing burden	Requires patient adherence
Manufacturing	Microsphere production and reconstitution	Conventional solid dosage manufacturing
Generic substitution	More technically complex	More straightforward
Patent value	Formulation and use claims	Historical active-ingredient and formulation claims

The formulation complexity supported a stronger practical barrier than would exist for an ordinary oral generic, although it also increased the risk that a court would narrowly construe claims or require detailed proof of infringement.

What litigation lessons does the case provide?

The case illustrates several strategic points for pharmaceutical companies:

1. A mature active ingredient can support substantial exclusivity when incorporated into a technically complex depot formulation.
2. Orange Book listing creates litigation leverage but does not validate the listed patent.
3. ANDA litigation may end without a public ruling, leaving commercial parties to rely on confidential settlement terms.
4. Injectable microsphere products create a combined patent, regulatory, and manufacturing barrier.
5. The absence of a final merits decision reduces the case’s value as precedent but does not eliminate its importance in lifecycle planning.
6. Patent term, FDA review timing, formulation redesign, and manufacturing capacity must be analyzed together.

Key Takeaways

• Alkermes sued Mylan in 2012 over an ANDA for a proposed generic version of Vivitrol.
• Vivitrol is an extended-release injectable naltrexone product based on polymeric microsphere technology.
• The dispute concerned formulation and controlled-release technology rather than naltrexone’s basic chemical composition.
• The case did not produce a reported public trial judgment resolving patent validity and infringement.
• The docket’s termination does not establish that Alkermes’ patents were upheld or that Mylan’s product was found non-infringing.
• Vivitrol’s competitive protection depended on Orange Book patents, FDA requirements, manufacturing know-how, and the difficulty of reproducing the depot formulation.
• The case had commercial importance as an early challenge to the patent estate protecting a complex injectable addiction-treatment product.

FAQs

Was Alkermes v. Mylan a Hatch-Waxman case?

Yes. The action followed Mylan’s ANDA filing and Paragraph IV patent challenge involving Vivitrol.

What was Vivitrol’s active ingredient?

Vivitrol contains naltrexone in an extended-release injectable microsphere formulation.

Did Mylan launch a generic Vivitrol product after the lawsuit?

The public case record does not establish a commercial launch resulting from this litigation.

Did the court invalidate Alkermes’ Vivitrol patents?

No reported final merits decision in the case establishes invalidity of the asserted patents.

Why are Vivitrol patents difficult to design around?

The product depends on controlled-release microspheres, manufacturing controls, particle characteristics, and predictable injection performance. A design-around may avoid patent claims but create separate FDA development and manufacturing risks.

References

1. U.S. District Court for the District of Delaware. (2012). Alkermes Pharma Ireland Limited v. Mylan Pharmaceuticals Inc., No. 1:12-cv-01673, docket records.

2. U.S. Food and Drug Administration. (2023). Vivitrol prescribing information. Alkermes, Inc.

3. Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. § 355(j).

4. U.S. Patent No. 6,228,398. (2001). Extended release microsphere compositions. U.S. Patent and Trademark Office.

5. U.S. Food and Drug Administration. (2016). Draft guidance for industry: ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of recombinant origin. FDA.